Interferon beta 1a inhalation - Synairgen

Drug Profile

Interferon beta 1a inhalation - Synairgen

Alternative Names: AZD-9412; SNG 0010; SNG-001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Southampton
  • Developer Synairgen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease
  • No development reported Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in United Kingdom (Inhalation, Aerosol)
  • 27 Sep 2017 Synairgen plans a phase IIb trial for Chronic obstructive pulmonary disease in early 2019
  • 27 Sep 2017 Exploratory efficacy data from phase II INEXAS and SG005 trials in Asthma released by Synairgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top